New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:31 EDTARWRArrowhead completes enrollment of first cohort in phase 2a trial of ARC-520
Arrowhead Research Corporation announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter. The Phase 2a study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen decline, among other measures, in response to a single dose of ARC-520.
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2014
07:31 EDTARWRArrowhead Research volatility at low end of one-year range
Subscribe for More Information
August 22, 2014
10:06 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: AMPE FOLD GME YOKU SPLS DKS WUBA ARWR ACHN
August 20, 2014
11:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 19, 2014
10:42 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 18, 2014
10:57 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 15, 2014
10:41 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: ARWR ICPT UVXY MNKD KING VIX SVXY VXX RAX OPK
August 14, 2014
11:46 EDTARWROptions with decreasing implied volatility
Subscribe for More Information
August 13, 2014
10:33 EDTARWROptions with decreasing implied volatility
Options with decreasing implied volatility: RPTP ARWR ZU ICPT MNKD UBNT OLED RAX UVXY VNDA
10:20 EDTARWRHigh option volume stocks
Subscribe for More Information
09:15 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:56 EDTARWRArrowhead should trade up on Hep B data, says RBC Capital
RBC Capital said Arrowhead's initial top-line Phase IIa data showed good knockdown of s-antigen, durability, and safety. The firm expects shares to trade up on the news and notes doctors say increased doses and time could lead to higher cures of Hep B. Shares are Outperform rated.
07:36 EDTARWRArrowhead shares recommended after ARC-520 data at Deutsche Bank
Subscribe for More Information
06:35 EDTARWRArrowhead shares likely weak on lack of data, says Piper Jaffray
Piper Jaffray expects shares of Arrowhead to be under pressure following the company's Q3 results given the lack of data for ARC-520 for the treatment of hepatitis-B virus infection. Piper keeps an Overweight rating on the stock with a $24 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use